BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 9662163)

  • 1. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA; Huang TC; Keyt BA; Alevriadou BR
    Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
    Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
    Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
    Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
    Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
    Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
    Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microfluidic Modeling of Thrombolysis.
    Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A faster-acting and more potent form of tissue plasminogen activator.
    Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen.
    Refino CJ; Paoni NF; Keyt BA; Pater CS; Badillo JM; Wurm FM; Ogez J; Bennett WF
    Thromb Haemost; 1993 Aug; 70(2):313-9. PubMed ID: 8236141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
    Wootton DM; Popel AS; Alevriadou BR
    Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.
    Braaten JV; Jerome WG; Hantgan RR
    Blood; 1994 Feb; 83(4):982-93. PubMed ID: 8111066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
    Van de Werf F; Barron HV; Armstrong PW; Granger CB; Berioli S; Barbash G; Pehrsson K; Verheugt FW; Meyer J; Betriu A; Califf RM; Li X; Fox NL;
    Eur Heart J; 2001 Dec; 22(24):2253-61. PubMed ID: 11728145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator.
    Stewart RJ; Fredenburgh JC; Leslie BA; Keyt BA; Rischke JA; Weitz JI
    J Biol Chem; 2000 Apr; 275(14):10112-20. PubMed ID: 10744692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
    Serebruany VL; Malinin AI; Callahan KP; Binbrek A; Van De Werf F; Alexander JH; Granger CB; Gurbel PA;
    Am Heart J; 2003 Apr; 145(4):636-42. PubMed ID: 12679759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.